In a model of the AD-like tau pathology (THY-Tau22 mice), the CYP46A1 gene therapy completely restored impaired cholesterol metabolism, rescued cognitive deficits, and mitigated impairments in long-term depression (LTD) as well as spine defects that characterize this model. Here, CYP46A1 is linked to Alzheimer disease.